Results 11 to 20 of about 39,548 (116)

Maintenance ECT in Recurrent Depression and Treatment Resistant Schizophrenia

Bezmiâlem Science, 2022
Objective:Electroconvulsive therapy (ECT) has been used for treatment of depression and psychosis for a long time. A less known way of use is as a maintenance treatment for keeping patients stable during remission. Recently ECT has been increasingly used
Sinem Zeynep METİN
doaj   +1 more source

Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response

Brain Sciences, 2022
Major depressive disorder is a leading cause of disability worldwide and a major contributor to the overall global burden of disease. While there are several options for antidepressant treatment, only about 40–60% of patients respond to initial ...
Theano Gkesoglou, Stavroula I. Bargiota, Eleni Iordanidou, Miltiadis Vasiliadis, Vasilios-Panteleimon Bozikas, Agorastos Agorastos   +5 more
doaj   +1 more source

Changes in sleep with transcranial magnetic stimulation in adults with treatment resistant depression: Preliminary results from a naturalistic study

European Psychiatry, 2021
Introduction Sleep disturbance specifically insomnia, non-restorative sleep, and hypersomnia are common symptoms of major depressive disorder (MDD).
A.I. Sonmez, R. Kay, S. Schmids, C. Peterson, A. Herman, A. Widge, Z. Nahas, C.S. Albott   +7 more
doaj   +1 more source

Treatment Resistant Depression and Sleep Apnea: A Case Report

Neuropsychiatric Investigation, 2015
Treatment resistance is an important issue in patients with depressive disorder and nearly a third of patients may not reach remission despite multiple drug trials.
Esra Aydın Sünbül, Hayal Ergin Toktaş, Hüseyin Güleç, Füsun Mayda Domaç, Ömer Yanartaş   +4 more
doaj   +1 more source

Clinical Guidelines of the Egyptian Psychiatric Association for the Management of Treatment-Resistant Unipolar Depression in Egypt

Frontiers in Psychiatry, 2022
BackgroundMajor depressive disorder (MDD) is a public health burden that creates a strain not only on individuals, but also on the economy. Treatment-resistant depression in the course of major depressive disorder represents a clinically challenging ...
Momtaz Abdel-Wahab, Tarek Okasha, Mostafa Shaheen, Mohamed Nasr, Tarek Molokheya, Abd ElNasser Omar, Menan A. Rabie, Victor Samy, Hany Hamed, Mohamed Ali   +9 more
doaj   +1 more source

A Southeast Asia Consensus on the Definition and Management of Treatment-Resistant Depression

Neuropsychiatric Disease and Treatment, 2022
Phern Chern Tor,1 Nurmiati Amir,2 Johnson Fam,3 Roger Ho,3 Pichai Ittasakul,4 Margarita M Maramis,5 Benita Ponio,6 Dharmawan Ardi Purnama,7 Wanida Rattanasumawong,8 Elizabeth Rondain,9 Ahmad Hatim Bin Sulaiman,10 Kannokarn Wiroteurairuang,11 Kok Yoon ...
Tor PC, Amir N, Fam J, Ho R, Ittasakul P, Maramis MM, Ponio B, Purnama DA, Rattanasumawong W, Rondain E, Bin Sulaiman AH, Wiroteurairuang K, Chee KY   +12 more
doaj  

All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population

Annals of General Psychiatry, 2019
Background Treatment-resistant depression (TRD) may represent a substantial proportion of major depressive disorder (MDD); however, the risk of mortality in TRD is still incompletely assessed. Methods Data were obtained from Optum Clinformatics™ Extended,
Gang Li, Daniel Fife, Grace Wang, John J. Sheehan, Robert Bodén, Lena Brandt, Philip Brenner, Johan Reutfors, Allitia DiBernardo   +8 more
doaj   +1 more source

Epidemiology of treatment resistant depression among major depressive disorder patients in Israel

BMC Psychiatry, 2022
Introduction Major depressive disorder (MDD) is one of the most common mental disorders worldwide, estimated to affect 10–15% of the population per year.
Sarah Sharman Moser, Gabriel Chodick, Shulamit Gelerstein, Nava Barit Ben David, Varda Shalev, Orit Stein-Reisner   +5 more
doaj   +1 more source

Overcoming the myths of esketamine administration: different and not difficult

Frontiers in Psychiatry, 2023
Intranasal esketamine for treatment-resistant depression has been introduced and approved by the FDA and EMA in 2019 and 2020, respectively. Since then, the administration practices were found different among countries. Major depression has a high impact
Florian Buchmayer, Siegfried Kasper
doaj   +1 more source

Characterizing Treatment-Resistant Anorexia Nervosa

Frontiers in Psychiatry, 2021
Background: The issue of treatment resistance in eating disorder care is controversial. Prior research has identified multiple failed treatment attempts as a common criterion for severe and enduring anorexia nervosa, but little is known about patients ...
Sarah Smith, D. Blake Woodside, D. Blake Woodside   +2 more
doaj   +1 more source